Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and all-trans-retinoic acid

被引:26
作者
Devy, L
Hollender, P
Munaut, C
Colige, A
Garnotel, R
Foidart, JM
Noel, A
Jeannesson, P
机构
[1] Univ Reims, Fac Pharm, Unite MeDIAN, CNRS,FRE 2141, F-51096 Reims, France
[2] Univ Liege, Lab Biol Tumeurs & Dev, Sart Tilman Par Liege, Belgium
[3] Univ Liege, Lab Biol Tissus Conjonctifs, Sart Tilman Par Liege, Belgium
[4] Fac Med, Lab Biochim Med & Biol Mol, CNRS, UPRESA 6021, F-51096 Reims, France
关键词
leukemia; ATRA; anthracyclines; cell invasion; MMPs; serine proteases;
D O I
10.1016/S0006-2952(01)00848-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In myeloid leukemia, immature leukemic cells are able to egress into peripheral blood to infiltrate extra-medullary organs. We therefore analyzed the migrating and invasive potential of human HL-60 and NB4 cell lines, representative of acute myelogenous leukemia, their ability to express matrix metalloproteases (MMPs), tissue inhibitors of metalloproteases (TIMPs) and urokinase plasminogen activator (uPA) in response to differentiating agents. Granulocytic differentiation by all-trans-retinoic acid (ATRA) and aclacinomycin (ACLA) strongly increased HL-60 and NB4 cell migration and invasion. At mRNA and protein levels, these cell lines produced significant amounts of MMP-9 (HL-60 < NB4). Granulocytic differentiation by ACLA increased both pro and active forms of MMP-9 whereas ATRA decreased them and stimulated uPA mRNAs. TIMP-1, the physiological MMP inhibitor, increased during granulocytic differentiation whereas TIMP-2 did not significantly vary. Use of Batimastat and aprotinin suggests that ATRA was active by modulating the uPA system while ACLA interfered with MMP expression. In conclusion, our data demonstrate that HL-60 and NB4 cells express MMPs and uPA which are differentially regulated by the differentiating agents ATRA and ACLA and suggest the clinical usefulness of MMPs and serine protease inhibitors in the prophylaxis and treatment of the ATRA syndrome. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:179 / 189
页数:11
相关论文
共 45 条
[1]   STIMULATED PRODUCTION OF UROKINASE AND PLASMINOGEN-ACTIVATOR INHIBITOR-2 BY THE HUMAN PROMYELOCYTIC LEUKEMIA-CELL LINE HL-60 [J].
ALVING, BM ;
KRISHNAMURTI, C ;
LIU, YP ;
LUCAS, DL ;
WRIGHT, DG .
THROMBOSIS RESEARCH, 1988, 51 (02) :175-185
[2]   Through and beyond the wall: late steps in leukocyte transendothelial migration [J].
Bianchi, E ;
Bender, JR ;
Blasi, F ;
Pardi, R .
IMMUNOLOGY TODAY, 1997, 18 (12) :586-591
[3]  
Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298
[4]   Tissue inhibitors of matrix metalloproteinases in cancer [J].
Blavier, L ;
Henriet, P ;
Imren, S ;
DeClerck, YA .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :108-119
[5]   Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding [J].
Botos, I ;
Scapozza, L ;
Zhang, DC ;
Liotta, LA ;
Meyer, EF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) :2749-2754
[6]  
BREITMAN TR, 1981, BLOOD, V57, P1000
[7]   RETINOIC ACID IS REQUIRED FOR AND POTENTIATES DIFFERENTIATION OF ACUTE PROMYELOCYTIC LEUKEMIA-CELLS BY NONRETINOID AGENTS [J].
CHEN, A ;
LICHT, JD ;
WU, Y ;
HELLINGER, N ;
SCHER, W ;
WAXMAN, S .
BLOOD, 1994, 84 (07) :2122-2129
[8]   CONTINUOUS GROWTH AND DIFFERENTIATION OF HUMAN MYELOID LEUKEMIC-CELLS IN SUSPENSION CULTURE [J].
COLLINS, SJ ;
GALLO, RC ;
GALLAGHER, RE .
NATURE, 1977, 270 (5635) :347-349
[9]   TERMINAL DIFFERENTIATION OF HUMAN PROMYELOCYTIC LEUKEMIA-CELLS INDUCED BY DIMETHYL-SULFOXIDE AND OTHER POLAR COMPOUNDS [J].
COLLINS, SJ ;
RUSCETTI, FW ;
GALLAGHER, RE ;
GALLO, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (05) :2458-2462
[10]   Dexamethasone does not counteract the response of acute promyelocytic leukaemia cells to all-trans retinoic acid [J].
De Ridder, MC ;
Van der Plas, AJ ;
Erpelinck-Verschueren, CAJ ;
Löwenberg, B ;
Jansen, JH .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (01) :107-110